Semaglutide denied as experimental or investigational by Anthem?

Anthem's specific coverage criteria for semaglutide are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Anthem Denied Semaglutide as "Experimental" — and Why This Is Contestable

An experimental or investigational denial from Anthem means Anthem's medical policy concluded that semaglutide lacks sufficient evidence of clinical benefit for the specific indication on your claim. For a drug with FDA approval, this almost always means one of three things: (1) the indication on your claim differs from the approved labeling and Anthem does not cover off-label use; (2) Anthem's clinical policy has not yet been updated to reflect a newer approved indication; or (3) the formulation involved is not FDA-approved. Understanding which scenario applies is the first step in your appeal.

## Why This Is Appealable

For FDA-approved indications, Anthem's experimental designation is difficult to sustain at external review, because FDA approval is itself the regulatory determination that evidence is sufficient. If your claim falls within an approved indication, the experimental classification is directly contradicted by the FDA's own finding. External reviewers — who are clinicians, not Anthem employees — frequently reverse experimental denials for FDA-approved indications.

## Your Federal Appeal Rights

• ERISA §503 / ACA §2719 internal appeal: You have the right to a full-and-fair review. Request Anthem's specific clinical policy and the evidence criteria it used to classify your treatment as experimental.
• External review (ACA §2719): Independent IRO review is available after the final internal denial. File within four months. External reviewers apply objective clinical standards, not Anthem's internal policy, which is why experimental denials often reverse at this stage.
• Expedited review: Request if standard timelines would jeopardize your health.

## What to Gather

1. Anthem's clinical policy document for semaglutide — request it by name. Identify the exact basis for the experimental classification. 2. FDA-approved prescribing information for the specific semaglutide product — the label lists every approved indication. Confirm your claim's indication is listed. 3. FDA approval letter or summary for the relevant indication — publicly available from FDA.gov; attach it as an exhibit. 4. Prescriber's medical-necessity letter: Should document the FDA-approved indication being treated, cite the applicable guideline organization (e.g., ADA, Obesity Medicine Association, ACC), and explain why semaglutide is the appropriate treatment for this patient. 5. Chart documentation of diagnosis and clinical course — confirming the indication is well-established, not speculative.

## Criteria-Mapping Structure

Obtain Anthem's evidence criteria for the experimental determination. For each criterion Anthem claims is unmet, respond with: the FDA approval status, a reference to the guideline organization's recommendation, and your prescriber's clinical rationale. Do not attempt to cite specific trial statistics — instead, reference the category of evidence (e.g., "FDA-approved based on pivotal randomized controlled trial evidence") and let the prescriber's letter carry the clinical argument.

## Key Argument

FDA approval is a legal and scientific determination that evidence is sufficient for safety and efficacy. An insurer's experimental classification of an FDA-approved drug for its approved indication is contradicted by the federal regulatory record.